Original language | English |
---|---|
Article number | e009778 |
Journal | Journal of the American Heart Association |
Volume | 7 |
Issue number | 20 |
DOIs | |
Publication status | Published or Issued - 1 Oct 2018 |
Externally published | Yes |
Keywords
- Apolipoprotein
- Primary prevention
- Randomized trial
- Regression
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of the American Heart Association, Vol. 7, No. 20, e009778, 01.10.2018.
Research output: Contribution to journal › Review article › peer-review
TY - JOUR
T1 - Eradicating the burden of atherosclerotic cardiovascular disease by lowering apolipoprotein b lipoproteins earlier in life
AU - Robinson, Jennifer G.
AU - Williams, Kevin Jon
AU - Gidding, Samuel
AU - Boršen, Jan
AU - Tabas, Ira
AU - Fisher, Edward A.
AU - Packard, Chris
AU - Pencina, Michael
AU - Fayad, Zahi A.
AU - Mani, Venkatesh
AU - Rye, Kerry Anne
AU - Nordestgaard, Børge G.
AU - Tybjærg-Hansen, Anne
AU - Douglas, Pamela S.
AU - Nicholls, Stephen J.
AU - Pagidipati, Neha
AU - Sniderman, Allan
N1 - Funding Information: Robinson, MD, MPH has received research grants to Institution: Amarin, Amgen, Astra-Zeneca, Esai, Esperion, Merck, Pfizer, Regeneron, Sanofi, Takeda (all significant) and served as a consultant for Akcea/Ionis, Amgen, Dr Reddy Laboratories, Eli Lilly, Merck, Pfizer (modest) and Regeneron and Sanofi (significant). Borén, MD, PhD has received research grant to Institution: Amgen, Astra-Zeneca, Pfizer, Sanofi/Regeneron and NovoNordisk (all significant), and served as consultant for Eli Lilly, AstraZeneca, MSD, Amgen, NovoNordisk (modest), Zahi Fayad, PhD has received research grants to institution from Amgen, Daiichi Sankyo (all significant). Fisher, MD, PhD has served as an expert witness for Amgen (significant) and is a member of the Merck Speaker’s Bureau. Gidding, MD has been a consultant for Regenxbio, not significant. Mani, PhD has received grants to institution from Daiichi Sankyo, Novartis and Aegerion (all significant) and is a consultant for Medlion Inc (modest). Nicholls, MD has received institutional grants from AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and honoraria from AstraZeneca, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion and Boehringer Ingelheim (modest). Nordestgaard, MD, DMSc has served as a consultant or has given talks sponsored by AstraZeneca, Sanofi, Regeneron, Ionis, Amgen, and Kowa (all modest). Packard, MD has received grants from Merck and Sanofi, and honoraria from Merck, Sanofi/Regeneron, Pfizer, Amgen and Daiichi-Sankyo. Pagidipati, MD reports grants to the institution from Sanofi/Regeneron, Alexion, Amgen, Verily, Novartis. Pencina, PhD reports grants to the institution from Sanofi/Regeneron. Rye, PhD acts as a consultant for CSL Limited (modest). Tabas, MD, PhD has served as a consultant for Merck, LipimetiX Development, Inc., and Novartis (modest). Williams, MD has ownership interests in Hygieia, Inc., and Gemphire Therapeutics, Inc. (both significant) and serves on the Medical and Scientific Advisory Board for Gemphire. The remaining authors have no disclosures to report. Funding Information: Gidding is supported by the Coronary Artery Risk Development in Young Adults Study (CARDIA) (contracts HHSN-268201300025C, HHSN268201300026C, HHSN26820130-0027C, HHSN268201300028C, HHSN268201300029C, and HHSN268200900041C from the National Heart, Lung, and Blood Institute [NHLBI], the Intramural Research Program of the National Institute on Aging [NIA], and an intra-agency agreement between NIA and NHLBI AG0005]). Tabas is supported by grants HL075662, HL132412, HL140554, and HL127464 from the National Heart, Lung, and Blood Institute (NHLBI). Fisher is supported by NIH grants HL 084312, 131481, 129433, and DoD grant 12019098. Fayad is supported by grants P01HL131478, 1R01HL128056, 2R01HL070121, R01EB009638, R01HL119828, R01HL-118440, R01HL125703, 1U01AR068043, R01HL135878, R01HL127637, R01HL135093 and R01AR068425 from the NIH and 14SFRN20780005 from the American Heart Association. Mani is supported by P01HL131478, 1R01HL128056, 2R01HL070121, 1U01AR068043, R01HL127637 from the NIH and 14SFRN20780005, 17GRNT33420119 from the American Heart Association. Rye has received support from the National Health and Medical Research Council of Australia APP1037903.
PY - 2018/10/1
Y1 - 2018/10/1
KW - Apolipoprotein
KW - Primary prevention
KW - Randomized trial
KW - Regression
UR - http://www.scopus.com/inward/record.url?scp=85055616825&partnerID=8YFLogxK
U2 - 10.1161/JAHA.118.009778
DO - 10.1161/JAHA.118.009778
M3 - Review article
C2 - 30371276
AN - SCOPUS:85055616825
SN - 2047-9980
VL - 7
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 20
M1 - e009778
ER -